<- Go Home
Revelation Biosciences, Inc.
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
Market Cap
$4.1M
Volume
669.1K
Cash and Equivalents
$6.5M
EBITDA
-$8.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$25.26
52 Week Low
$0.70
Dividend
N/A
Price / Book Value
1.53
Price / Earnings
-0.09
Price / Tangible Book Value
1.53
Enterprise Value
-$2.5M
Enterprise Value / EBITDA
0.29
Operating Income
-$8.5M
Return on Equity
270.02%
Return on Assets
-50.98
Cash and Short Term Investments
$6.5M
Debt
N/A
Equity
$2.7M
Revenue
N/A
Unlevered FCF
-$6.5M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium